Introduction Despite the publication of multiple evidence-based guidelines recommending against routine
INTRODUCTION
Breast cancer is the most common cancer in Canadian women, with an estimated 25,000 new cases annually [1] [2] [3] . A new diagnosis of breast cancer has considerable cost implications for both the patient and the health care system. In recent years, national (http://www.choosingwiselycanada. org) and international (http://www.choosingwisely.org) drives through the Choosing Wisely initiative have set out to ensure the most appropriate use of resources. In response to Choosing Wisely, the American Society of Clinical Oncology published its recommendations on best practices in oncology, advocating against the use of radiologic imaging for distant metastatic disease in asymptomatic patients with pathologic early-stage (i/ii) breast cancer 4 . The American Society of Clinical Oncology based its recommendation in part on the low incidence of radiologically evident metastases in early-stage disease (0.2%-1.2%) 5 .
In Ca nada, Ca ncer Ca re Onta r io recommends against imaging for patients with stage i disease and bone scans for those with stage ii disease 6 . Although imaging might offer little to no benefit and might be harmful, recent evidence nevertheless shows that most patients still undergo imaging for metastatic cancer regardless of their disease stage 7 . The objective of the present study was therefore to estimate and describe the cost of unwarranted imaging in women diagnosed with stage i or ii breast cancer in Ontario.
METHODS
We used provincial health administrative datasets housed at the Institute for Clinical Evaluative Sciences to conduct a retrospective population-based cohort study. Using the Ontario Cancer Registry, all women who were diagnosed with early-stage (i/ii) breast cancer between 2007 and 2012 were identified. This Ontario Cancer Registry cohort was linked with the Discharge Abstract Database maintained by the Canadian Institute for Health Information to identify patients who underwent breast-related surgeries and with the Ontario Health Insurance Plan to identify all claims made by physicians (and other health care providers) for insured services provided to residents of Ontario. A detailed description of the study cohort has been published elsewhere 7 .
To ascertain that only primary operable patients were included, our study population was restricted to patients with a first diagnosis of breast cancer who underwent surgery within 3 months of a tissue diagnosis date. Patients with an earlier breast cancer diagnosis or stage 0 (including ductal carcinoma in situ), iii, iv, null, or unknown disease at the index year were excluded.
Imaging was identified in the Ontario Health Insurance Plan database through imaging fee codes and was classified by body site (skeleton; thorax; abdomen or pelvis, or both; other) and modality (bone scan, computed tomography, magnetic resonance imaging, ultrasonography, radiography, positron-emission tomography). Given that the pattern of imaging can depend on an imaging sequence, we also categorized imaging as initial or confirmatory. "Initial imaging" was defined as the first imaging test performed on a body site in the pre-specified time period. "Confirmatory imaging" was defined as the second imaging test performed on a body site that had already been imaged.
For the present study, we estimated the cost of unwarranted imaging under two scenarios. In the first scenario, we adopted the American Society of Clinical Oncology recommendation and defined an unwarranted imaging test as preoperative or postoperative imaging performed in asymptomatic women with pathologic stage i or ii breast cancer. In the second scenario, we defined unwarranted imaging using the Cancer Care Ontario recommendation to forgo imaging for patients with stage i and ii disease and bone scans for those with stage ii disease.
The cost of unwarranted imaging was calculated by multiplying the frequency of each unwarranted imaging test by its unit cost, which included both the professional and the technical components, obtained from Schedule of Benefits for Physician Services 8 and the published literature 9 . The total cost of unwarranted imaging tests was equal to the sum of imaging costs incurred during 2007-2012 and was stratified by disease stage, modality, and body site. All costs are expressed in 2015 Canadian dollars. All analyses were performed using R software application (version 3.2.2 for Windows: The R Foundation, Vienna, Austria). 
RESULTS

Of
The anatomic areas most imaged ( Figure 1) were the abdomen and pelvis (either or both: 34.5%), the thorax (33.5%), and the skeleton (29.0%). The three most common imaging modalities were radiography, ultrasonography, and bone scan. Figure 1(A) shows that the distribution of imaging tests by modality was similar for each disease stage. The proportion of imaging tests varied according to the sequence of imaging tests. The most common site for initial imaging was abdomen and pelvis (either or both: 37.1%), followed by thorax (32.2%) and skeleton (27.5%). The most common site for confirmatory imaging was the thorax (37.7%), followed by the skeleton (33.8%), and abdomen and pelvis (either or both: 26.2%). 7%) represented the second and third cost drivers respectively. For patients with stage ii breast cancer, computed tomography was the second-largest cost driver (22.7%), followed by radiography (21.2%). Figure 1(B) shows that the cost of imaging tests also depended on the anatomic area imaged, with skeletal imaging proving to be the most expensive, followed by imaging of abdomen and pelvis and of thorax.
Based on the American Society of Clinical Oncology recommendation, 83,249 excess imaging procedures were performed, costing CA$6,865,856 for the 5-year period of interest. Similarly, according to the Cancer Care Ontario recommendation, 45,127 imaging tests were deemed unwarranted, costing CA$4,418,139.32 for the 5-year period (Table ii) .
DISCUSSION AND CONCLUSIONS
As health care costs continue to rise, attention has been paid to increasing the efficiency of health care delivery. Several initiatives, including the Choosing Wisely campaign and Choosing Wisely Canada, have focused on eliminating wasteful or unwarranted health care services that provide little or no health benefit to patients 4, 5 .
In previous studies 7,10 , we observed excess imaging at the local and provincial level, and in the present study, we evaluated the cost implications of unwarranted imaging in a large cohort of all primary operable breast cancer patients in Ontario. Our study shows that the cost of excess imaging was substantial. Higher imaging costs in stage ii patients could indicate that patients with increased disease severity had a worse prognosis and might have required more frequent pre-and postoperative assessment and follow-up. Our results are consistent with those of Mittmann et al. 11 , who suggested that, compared with patients at other disease stages, patients with stage ii breast cancer consumed the largest overall total health care cost-mainly because they had more frequent cancer clinic visits, more physician claims, and were hospitalizations.
Although radiography was the most common imaging modality, bone scans accounted for the largest cost component (CA$2,947,398), chiefly because of high frequency and the high unit cost of bone scintigraphy. The greater frequency of bone scans could be related to the fact that bone is the most common site of breast cancer recurrence 12 ; however, fewer than 2% of asymptomatic patients with pathology-confirmed stage ii disease will have radiologic evidence of overt bone metastases 5 .
Our study does not take into account physician visits, follow-up tests, or referrals to specialists that might have resulted from medical imaging. If those costs were to be included, the cost of unwarranted imaging to the health care system would be much larger. It is possible that some imaging tests might have been ordered for purposes other than assessment for metastasis; however, we were not able to determine the intent of each imaging test.
In summary, this study highlights a large portion of health care costs that could be saved or reallocated if practice guidelines for medical imaging in patients with early-stage breast cancer were adhered to. Strategies aimed at patients 13, 14 and physicians 10, 15 should be implemented to promote adherence to practice guidelines. 
